Abstract
Pathogens that produce extended spectrum β-lactamases (ESBLs), plasmid-mediated AmpC β-lactamases, and carbapenemases may appear falsely susceptible to β-lactam antibiotics in the laboratory. Infected patients may be treated with inappropriate antibiotics if laboratories do not perform accurate tests to detect these resistance mechanisms. Furthermore the resistant pathogens may spread undetected to amplify the therapeutic and infection control challenge. This review makes a case for why and how laboratories should perform tests to detect β-lactamase-mediated resistance in gram-negative pathogens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
